Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19.
Two newly repositioned drugs with the potential to combat key symptoms of COVID-19 were announced on Aug. 25 by bioscience firm Biovista. The firm identified Cablivi and Atozet as particularly suited to target specific aspects of blood clotting and inflammation in the context of COVID-19.
This follows a mechanistic rationale Biovista released in March, suggesting Aprotinin and Irbesartan as potential COVID-19 treatments to reduce the effects of the cytokine storm, as well as helping reduce viral loads.
For more information, click here.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.